Press Releases AstraZeneca PLC Nasdaq

Equities

AZN

US0463531089

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-21 EDT			5-day change	1st Jan Change
79.18 ^USD	+2.68%		+2.78%	+17.56%

05-21	US Equity Indexes Little Changed as Fed Officials Pepper Views on Policy Path, Investors Brace for Nvdia's Earnings	MT
05-21	US Equity Indexes Slightly Higher in Midday Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca : Oncology presentation	05-21	PU
AstraZeneca : Rare Disease presentation	05-21	PU
AstraZeneca : BioPharmaceuticals presentation	05-21	PU
AstraZeneca : Investor Day Agenda	05-21	PU
AstraZeneca : Investor Day Biographies	05-21	PU
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030	05-21	BU
Astrazeneca set to build cancer drug plant in Singapore	05-21	AQ
AstraZeneca announces $1.5b ADC manufacturing facility	05-20	AQ
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	05-20	AQ
AstraZeneca : plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K	05-20	PU
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	05-19	BU
AlzeCure Pharma AB - Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member	05-16	AQ
AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K	05-16	PU
Insights into AstraZeneca's MANDARA Phase III data	05-16	AQ
Notice to the Annual General Meeting of Cline Scientific AB	05-16	AQ
AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K	05-15	PU
Eli Lilly’s and AstraZeneca’s former head of research Dr. Jan Lundberg elected as a new board member	05-15	AQ
AstraZeneca pulls its COVID-19 vaccine from the European market	05-08	AQ
ANGLE PLC - NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA	05-06	AQ
Combination treatment could provide new standard-of-care for aggressive lymphoma	05-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm